登录 | 注册    关注公众号  
微信公众号
搜索
 > 【CD39】

CD39信息

英文名称:Ectonucleoside triphosphate diphosphohydrolase 1
中文名称:外核苷三磷酸二磷酸水解酶-1
靶点别称:CD39 Antigen,CD39,EC 3.6.1.5,NTPDase-1,NTPDase 1,ATPDase,SPG64,EC:3.6.1.5,Ecto-ATPase 1,Lymphoid cell activation antigen,ENTPD1,Ectonucleoside Triphosphate Diphosphohydrolase 1,Ecto-ATPDase 1,Ecto-Apyrase,Ecto-ATP diphosphohydrolase 1,EC 3.6.1
上市药物数量:0
临床药物数量:9
最高研发阶段:临床二期

CD39产品列表

ACRO质量管理体系
 
评论(3)
CD9-H52H4|Human CD39 / ENTPD1 Protein, His Tag (active enzyme, MALS verified)
  1. 136XXXXXXX6
  2. 18人赞
  3. 购买蛋白用于测试CD39封闭性抗体封闭CD39水解ATP的功能实验。通过系列梯度CD39抗体与一定浓度的CD39(0.5ug/ml)孵育,再加入50uM ATP,用CTG检测,得到很好的曲线。证明该蛋白具有很好的ATP酶水解功能。
  4. 2019-11-11
CD9-H52H4|Human CD39 / ENTPD1 Protein, His Tag (active enzyme, MALS verified)
  1. 180XXXXXXX9
  2. 3人赞
  3. 购买CD39用于动物免疫、后续抗体筛选和检测。抗原蛋白通过检测,纯度、活性方面都非常好,目前已准备免疫,期待获得良好的免疫效果。
  4. 2021-12-09
CD9-H52H7|Human CD39 (R138A, M139A, E142K) Protein, His Tag (active enzyme)
  1. 188XXXXXXX4
  2. 0人赞
  3. 这款产品使用效果非常好,用来做酶联免疫检测非常稳定,而且具有结果分明,容易判断的优点,对于实验重现很有帮助!真不错!
  4. 2023-10-26
 

CD39分子别名

CD39,ENTPD1,NTPDase 1,Entpd1,Ecto-ATPDase 1,Ecto-ATPase 1

CD39分子背景

CD39 is also known as Ectonucleoside triphosphate diphosphohydrolase 1, ENTPD1, NTPDase 1, Ecto-ATPDase 1, in the nervous system, could hydrolyze ATP and other nucleotides to regulate purinergic neurotransmission. Could also be implicated in the prevention of platelet aggregation by hydrolyzing platelet-activating ADP to AMP. Hydrolyzes ATP and ADP equally well. NTPDase-1 was originally described as CD39, a B lymphocyte cell surface marker, but it is also present on the surface of natural killer cells, T cells, and some endothelial cells.Regulatory T cells(Tregs) mediate immunosuppression through multiple, non-redundant, cell-contact dependent and independent mechanisms, a growing body of evidence suggests an important role for the CD39-CD73-adenosine pathway. CD39 ectonucleotidase is the rate-limiting enzyme of a cascade leading to the generation of suppressive adenosine that alters CD4 and CD8 T cell and natural killer cell antitumor activities.

CD39临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Perenostobart SRF-617 临床二期 Surface Oncology Inc 实体瘤, 去势抵抗性前列腺肿瘤, 前列腺癌 详情
IPH-5201 IPH-5201 临床二期 Inserm, Orega Biotech 实体瘤, 肺癌, 非小细胞肺癌 详情
AB-598 AB598 临床一期 Arcus Biosciences Inc 卵巢癌, 肾细胞癌, 胃癌, 食道癌, 头颈部鳞状细胞癌, 肿瘤, 三阴性乳腺癌, 膀胱癌, 非小细胞肺癌, 宫颈癌 详情
Eurestobart ES-002023 临床一期 科望(上海)生物医药科技有限公司 实体瘤 详情
ES-002 ES-002 临床一期 科望(上海)生物医药科技有限公司 实体瘤, 肿瘤 详情
PUR-001 PUR-001 临床一期 Purinomia Biotech Inc 实体瘤 详情
TTX-030 TTX-030 临床二期 Adimab LLC 实体瘤, 胰腺癌, 淋巴瘤 详情
ES-014 ES-014 临床一期 科望(上海)生物医药科技有限公司 实体瘤, 肿瘤, 转移癌 详情
JS-019 JS-019 临床一期 北京恩瑞尼生物科技股份有限公司 实体瘤, 淋巴瘤 详情

消息提示

请输入您的联系方式,再点击提交!

确定